Improvement in the quality of molecular analysis of EGFR in non-small-cell lung cancer detected by three rounds of external quality assessment
- Zandra C Deans1,
- Neil Bilbe2,
- Brendan O'Sullivan3,
- Lazarus P Lazarou4,
- David Gonzalez de Castro5,
- Suzanne Parry2,
- Andrew Dodson2,6,
- Philippe Taniere3,
- Caroline Clark7,
- Rachel Butler4
- 1Department of Laboratory Medicine, UK NEQAS for Molecular Genetics, UK NEQAS Edinburgh, The Royal Infirmary of Edinburgh, Edinburgh, UK
- 2UK NEQAS for Immunocytochemistry and In-Situ Hybridisation, London, UK
- 3Department of Cellular Pathology, Queen Elizabeth Hospital, Birmingham, UK
- 4All Wales Molecular Genetics Laboratory, University Hospital of Wales, Cardiff, UK
- 5Molecular Diagnostics, The Royal Marsden NHS Foundation Trust, Surrey, UK
- 6Department of Cellular Pathology, Royal Liverpool University Hospital, Liverpool, UK
- 7Aberdeen Regional Genetics Service, Department of Medical Genetics, Grampian NHS Trust, Aberdeen, UK
- Correspondence to Dr Zandra C Deans, Department of Laboratory Medicine, UK NEQAS for Molecular Genetics, UK NEQAS Edinburgh, The Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK;
- Received 20 September 2012
- Revised 13 November 2012
- Accepted 27 November 2012
- Published Online First 1 February 2013
Background The clinical need to determine the presence of epidermal growth factor receptor (EGFR) gene mutations in non-small-cell lung cancers (NSCLC) in order to make informed decisions for patient treatment has seen the widespread introduction of EGFR molecular testing in many laboratories. To ensure high-quality molecular testing and allow laboratories to externally measure the standard of the service, an external quality assessment (EQA) scheme was provided to assess the whole testing process.
Methods Formalin-fixed paraffin-embedded NSCLC tumour sections were distributed to laboratories for routine EGFR molecular testing, and the genotyping accuracy, interpretation of the result and clerical accuracy of the report were independently assessed.
Results Three rounds of assessment have identified many genotyping errors and have highlighted the need for external assessment and education in many testing laboratories. The main issues raised were the importance of accurate genotyping, including the use of common mutation nomenclature, clear unambiguous interpretation of the result, the impact of tumour sample assessment regarding amount of tumour being analysed and the heterogeneity of the sample on the molecular test result.
Conclusions Improvements in all these areas were observed during the progression of the three EQA rounds, however, continuous unacceptably high genotyping error rates demonstrate the clear need for continual external assessment and education in this field.